Asian Oncology Nursing (종양간호연구)

Korean Oncology Nursing Society (대한종양간호학회)
권호 표지
DOI QR코드

DOI QR Code

Compliance with the Protocol Considered Emetogenic Potential for Prophylaxis of Chemotherapy Induced Nausea and Vomiting

항암화학요법의 구토유발 수준별 예방적 항구토제 프로토콜의 이행정도

  • Choi, Ja-Yun (College of Nursing, Chonnam National University, Chonnam Research Instutude of Nursing Science) ;
  • Oh, Hyeon-Jeong (College of Nursing, Chonnam National University) ;
  • Kang, Ji-Young (College of Nursing, Chonnam National University) ;
  • Kim, Min-Kyoung (College of Nursing, Chonnam National University) ;
  • Kim, Ji-Eun (College of Nursing, Chonnam National University) ;
  • Kim, Jin-Ha (College of Nursing, Chonnam National University) ;
  • Kim, Hee-Suk (College of Nursing, Chonnam National University) ;
  • Park, So-Ra (College of Nursing, Chonnam National University) ;
  • Byun, Jeong-Seon (College of Nursing, Chonnam National University) ;
  • An, Jeong-Hee (College of Nursing, Chonnam National University) ;
  • Cho, Min-Kyoung (College of Nursing, Chonnam National University)
  • 최자윤 (전남대학교 간호대학.전남대학교 간호과학연구소) ;
  • 오현정 (전남대학교 대학원 간호학과) ;
  • 강지영 (전남대학교 대학원 간호학과) ;
  • 김민경 (전남대학교 대학원 간호학과) ;
  • 김지은 (전남대학교 대학원 간호학과) ;
  • 김진하 (전남대학교 대학원 간호학과) ;
  • 김희숙 (전남대학교 대학원 간호학과) ;
  • 박소라 (전남대학교 대학원 간호학과) ;
  • 변정선 (전남대학교 대학원 간호학과) ;
  • 안정희 (전남대학교 대학원 간호학과) ;
  • 조민경 (전남대학교 대학원 간호학과)
  • Received : 2010.12.10
  • Accepted : 2011.01.12
  • Published : 2011.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The purpose of this study was to identify the compliance with the protocol, which was developed considering the emetogenic potential for prophylaxis of chemotherapy. Methods: Data was collected from 144 patients who received chemotherapy from June 15 to August 31, 2010 in C University Hospital in Jeollanamdo, Korea. The level of chemotherapy-induced nausea and vomiting (CINV) and the compliance with the protocol for prophylaxis of CINV were measured. Results: There was statistically significant difference of CINV in morning sickness and anticipatory nausea of general and clinical characteristics. Also, the compliance with the protocol developed according to emetogenic potential of chemotherapy was statistically significant. There was no difference in CINV in regard to the compliance with the protocol. Conclusion: There was a good compliance with the protocol for prophylaxis according to emetogenic potential. But it should be recommended to use antiemetics for prophylaxis aggressively to relieve CINV for the patients who already experienced morning sickness and anticipatory nausea. In addition, the oncology nurses should respond sensitively to the complaints of nausea and vomiting no matter what the emetogenic potentials of chemotherapy regimen are.

Keywords

References

  1. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, et al. Cancer statistics in Korea: Incidence, mortality and survival in 2006-2007. J Korean Med Sci 2010;25:1113-21. https://doi.org/10.3346/jkms.2010.25.8.1113
  2. Jordan K, Sippel C, Schmoll HH. Guidelines for antiemetic treatment of chemotherapy induced nausea and vomiting: past. present, future recommendations. Oncologist 2007;12:1143-50. https://doi.org/10.1634/theoncologist.12-9-1143
  3. Oh CY, Yun HY, Lim EH, Kim ON. Evaluation of antiemetic therapy after the administration of high-dose antineoplastic agents: Focused Ondansetron. J Korean Soc Health Syst Pharm 1999;16:495-500.
  4. Kwon SJ. A recommendation of antiemetics. Korean J Clin Oncol 2006; 2:30-5.
  5. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-47. https://doi.org/10.1200/JCO.2006.06.9591
  6. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-9. https://doi.org/10.1200/JCO.1997.15.1.103
  7. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-47. https://doi.org/10.1200/JCO.2006.06.9591
  8. Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Ann Oncol 1998;9:811-9. https://doi.org/10.1023/A:1008471812316
  9. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999;17:2971-94. https://doi.org/10.1200/JCO.1999.17.9.2971
  10. European Society for Medical Oncology. ESMO recommendations for prophylaxis of chemotherapy-induced nauseaand vomiting (NV). Ann Oncol 2001;12:1059-60. https://doi.org/10.1023/A:1017413507554
  11. National Comprehensive Cancer Network. Effective interventions for CINV: NCCN Antiemesis Clinical Practice Guidelines in Oncology. ONS News 2004;19(9 Suppl):17-8.
  12. Herrstedt J, Roila F. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 2008; 19(Suppl 2):ii110-2.
  13. Asan Medical Center Cancer Center. Clinical practice guideline for Chemotherapy. Seoul: Koonja publishers;2009.
  14. Wickham R. Best practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for use. J Support Oncol 2010;8(2 Suppl 1):10-5.
  15. Shih V, Wan HS, Chan A. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Ann Pharmacother 2009;43:444-52. https://doi.org/10.1345/aph.1L437
  16. Warr DG. Chemotherapy -and cancer-related nausea and vomiting. Curr Oncol 2008;15(Supplement 1):S4-9.
  17. Mertens WC, Higby DJ, Brown D, Parisi R, Fitzgerald J, Benjamin EM, et al. Improving the care of patients with regard to chemotherapy induced nasuea and emesis: The effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 2003;21:1373-8. https://doi.org/10.1200/JCO.2003.08.118
  18. Rhodes VA. Criteria for assessment of nausea, vomiting, and retching. Oncol Nurs Forum 1997;24(7 Suppl):13-9.
  19. Rhodes VA, Mcdaniel RW. The index of nausea, vomiting and retching: a new format of the Index of Nausea and Vomiting. Oncol Nurs Forum 1999;26:889-94.
  20. Kim YJ, Kim JY, Choi IR, Kim MW, Rhodes VA. The index of nausea, vomiting and retching(Korean translation). J Korean Acad Adult Nurs 2000;12:278-85.
  21. Molassiotis A, Yam BM, Yung H, Chan FY, Mok TS. Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care cancer 2001;10: 139-45.
  22. Molassiotis A, Brearley SG, Stamataki Z. Use of antiemtics in the management of chemotherapy-related nausea and vomiting in current UK practice. Support Care Cancer [arcessed on 2 June 2010]. Available at: http://www.springerlink.com/content/lg36372wlx3587p0/
  23. Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004;15:526-36. https://doi.org/10.1093/annonc/mdh110
  24. Grelot L, Dapzol J, Esteve E, Frugiere A, Bianchi AL, Sheldrick RL, et al. Potent inhibition of both the acute and delayed emetic responses to cisplatin in piglets treated with GR205171, a novel highly selective tachykinin NK1 receptor antagonist. Br J Pharmacol 1998;124:1643-50. https://doi.org/10.1038/sj.bjp.0702019